Fig. 2: Mutational profiles of NSCLC patients from Taiwan. | Cell Death Discovery

Fig. 2: Mutational profiles of NSCLC patients from Taiwan.

From: Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer

Fig. 2

Patients who received first-line treatment were enrolled at Taipei Veterans General Hospital and their genomic alterations were analyzed using targeted re-resequencing. A, B Show the variant type and classification. C Depicts the top 20 gene mutation profiles for each patient. D Represents the positions of TP53 mutations in NSCLC patients from Taiwan.

Back to article page